Advaxis, Inc. is a late-stage biotechnology company creating cancer immunotherapies that enlist the body’s own immune system to fight cancer. Advaxis’ proprietary Lm targeted immunotherapy is a new approach toward an effective cancer vaccine, and has achieved safety and efficacy endpoints in early-stage trials. Lm Technology is the platform for our continued focus on the science, discovery, development and commercialization of cutting-edge cancer treatments.

Rosetta Genomics is a leading developer of microRNA-based molecular diagnostics. Founded in 2000, the company’s integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong IP position and proprietary platform technologies, Rosetta Genomics is working on the application of these technologies in the development of microRNA-based assays that address important unmet needs . The company’s lead microRNA-based tests are its RosettaGX Reveal (a Thyroid microRNA classifier) and RosettaGX Cancer Origin for cancer of unknown and uncertain primary. These assays are commercially available through its Philadelphia-based CLIA-certified lab. Medicare covers the Cancer Origin assay.

Member of J&J Law Department; handled M&A and other corporate law matters